Capricor Therapeutics(CAPR)2024-05-14 13:00Financial Position - As of March 31, 2024, Capricor Therapeutics had cash, cash equivalents, and marketable securities totaling approximately 39.9 million[396]. - The investment portfolio as of March 31, 2024, consisted primarily of money market funds and short-term U.S. treasuries[87]. - Capricor's current cash balance is expected to fund operating expenses and capital expenditures into Q1 2025, excluding potential milestone payments[396]. Revenue Generation - Capricor has not generated any revenues from the commercial sale of products and will not be able to do so until FDA approval is obtained[396]. Research and Development - R&D expenses are expected to increase due to additional non-cash compensation expenses in the future[401]. - There was a 0.5 million increase in stock-based compensation expense primarily due to an increase in the risk-free rate and stock price[405]. - The company is collaborating with an undisclosed pharmaceutical company to investigate the therapeutic application of its StealthX™ exosome platform[399]. - Data presented at the ASGCT 27th Annual Meeting highlighted a potential exosome-based approach for treating arginase-1 deficiency[399]. Milestones and Analysis - In Q4 2023, a positive outcome of the interim futility analysis for the HOPE-3 trial was announced, leading to a milestone payment of $10.0 million received in January 2024[396]. Internal Controls - There has been no change in internal control over financial reporting that materially affected the company during the quarter ended March 31, 2024[89].